Breaking News Instant updates and real-time market news.

LXRX

Lexicon

$15.23

-1.1 (-6.74%)

06:13
12/22/16
12/22
06:13
12/22/16
06:13

Citi disagrees with market view on Lexicon Pharmaceuticals

After shares of Lexicon Pharmaceuticals fell 7% yesterday following data from the second Phase 3 testing sotagliflozin in Type 1 diabetes, Citi analyst Yigal Nochomovitz says he disagrees with the market view. Investors are "getting too bogged" down on the safety question, the analyst tells investors in a research note. The data "unambiguously solve a major clinical challenge" in Type 1, which is getting A1c lower without the expense of glycemic excursions and thus more hypos, Nochomovitz writes. He keeps a Buy rating on Lexicon with a $24 price target.

  • 19

    Jan

  • 28

    Feb

LXRX Lexicon
$15.23

-1.1 (-6.74%)

08/02/16
SBSH
08/02/16
INITIATION
Target $21
SBSH
Buy
Lexicon initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started Lexicon Pharmaceuticals with a Buy rating and $21 price target. The analyst expects "timely approval and launch" of the company's lead drug telotristat etiprate, an add-on to standard of care to treat severe diarrhea in carcinoid syndrome patients. He believes this should provide near-term support for the stock.
09/12/16
SBSH
09/12/16
NO CHANGE
Target $25
SBSH
Buy
Lexicon price target raised to $25 from $21 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Lexicon Pharmaceuticals to $25 saying sotagliflozin showed "strong efficacy" in its first Phase 3 trial in Type 1 diabetes mellitus. The analyst believes concerns over Sotagliflozin safety should be lifted on these data. He reiterates a Buy rating on Lexicon.
10/07/16
HCWC
10/07/16
INITIATION
Target $26
HCWC
Buy
Lexicon initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak started Lexicon Pharmaceuticals with a Buy rating and $26 price target.
12/21/16
12/21/16
NO CHANGE

Lexicon's sotagliflozin meets primary endpoint in Phase 3 trial for diabetes
Lexicon Pharmaceuticals' pivotal inTandem2 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in patients with type 1 diabetes on optimized insulin therapy. Top-line results from the Phase 3 study showed that patients treated with sotagliflozin had mean A1C reductions from baseline of 0.39% on 200mg once daily sotagliflozin dose and 0.37% on 400mg once daily sotagliflozin dose as compared to a reduction of 0.03% on placebo after 24 weeks of treatment, meeting the study's primary endpoint. This statistically significant and clinically meaningful improvement in A1C for both doses of sotagliflozin was achieved with a favorable overall safety profile in the study, including rates of severe hypoglycemia similar to placebo and low overall rates of diabetic ketoacidosis.

TODAY'S FREE FLY STORIES

KO

Coca-Cola

$45.71

-0.84 (-1.80%)

08:46
11/20/17
11/20
08:46
11/20/17
08:46
Recommendations
Coca-Cola analyst commentary  »

Coca-Cola investor day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$40.82

8.97 (28.16%)

08:45
11/20/17
11/20
08:45
11/20/17
08:45
Recommendations
Foot Locker analyst commentary  »

Foot Locker price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:45
11/20/17
11/20
08:45
11/20/17
08:45
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

JNJ

Johnson & Johnson

$138.00

-0.87 (-0.63%)

08:43
11/20/17
11/20
08:43
11/20/17
08:43
Hot Stocks
EU extends license for Janssen's Zytiga plus prednisone »

Janssen-Cilag…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

LIVN

LivaNova

$84.32

0.04 (0.05%)

08:42
11/20/17
11/20
08:42
11/20/17
08:42
Recommendations
LivaNova analyst commentary  »

LivaNova received fair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 01

    Dec

MNST

Monster Beverage

$62.17

0.17 (0.27%)

, KO

Coca-Cola

$45.71

-0.84 (-1.80%)

08:40
11/20/17
11/20
08:40
11/20/17
08:40
Downgrade
Monster Beverage, Coca-Cola rating change  »

Monster Beverage…

MNST

Monster Beverage

$62.17

0.17 (0.27%)

KO

Coca-Cola

$45.71

-0.84 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NQ

NQ Mobile

$4.05

-0.05 (-1.22%)

08:40
11/20/17
11/20
08:40
11/20/17
08:40
Hot Stocks
NQ Mobile provides update on FL Mobile Divestment »

NQ Mobile provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENSG

Ensign Group

$23.77

0.22 (0.93%)

08:38
11/20/17
11/20
08:38
11/20/17
08:38
Recommendations
Ensign Group analyst commentary  »

Ensign Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRVL

Marvell

$20.29

0.03 (0.15%)

, CAVM

Cavium

$75.83

-0.47 (-0.62%)

08:37
11/20/17
11/20
08:37
11/20/17
08:37
Hot Stocks
Marvell: Cavium deal doesn't include divestitures, changes to Cavium's portfolio »

On the conference call…

MRVL

Marvell

$20.29

0.03 (0.15%)

CAVM

Cavium

$75.83

-0.47 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

BKS

Barnes & Noble

$7.45

0.35 (4.93%)

08:35
11/20/17
11/20
08:35
11/20/17
08:35
Hot Stocks
Barnes & Noble announces Black Friday weekend deals »

Barnes & Noble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

ARAY

Accuray

$4.80

-0.1 (-2.04%)

08:35
11/20/17
11/20
08:35
11/20/17
08:35
Technical Analysis
Technical View: Accuray rallies in pre-market »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNUS

Genius Brands

$2.88

0.02 (0.70%)

08:34
11/20/17
11/20
08:34
11/20/17
08:34
Hot Stocks
Genius Brands signs multiple content sales deals for children's programming »

Genius Brands expands the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$34.95

-0.33 (-0.94%)

08:34
11/20/17
11/20
08:34
11/20/17
08:34
Initiation
Aimmune initiated  »

Aimmune initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

WOR

Worthington

$40.24

0.03 (0.07%)

08:33
11/20/17
11/20
08:33
11/20/17
08:33
Hot Stocks
WAVE to sell EMEA, Pacific Rim units »

Worthington (WOR)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTIV

On Track Innovations

$1.13

-0.01 (-0.88%)

08:32
11/20/17
11/20
08:32
11/20/17
08:32
Hot Stocks
On Track Innovations: UNO 6 selected by CityEV as cashless payment solution »

On Track Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MDSO

Medidata

$68.64

-0.85 (-1.22%)

08:32
11/20/17
11/20
08:32
11/20/17
08:32
Hot Stocks
Medidata, MEL MEDICAL announce multi-year Medidata eTMF agreement »

Medidata announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

PNTR

Pointer Telocation

$17.55

-0.2 (-1.13%)

08:30
11/20/17
11/20
08:30
11/20/17
08:30
Downgrade
Pointer Telocation rating change  »

Pointer Telocation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZH

Beazer Homes

$20.50

0.04 (0.20%)

08:29
11/20/17
11/20
08:29
11/20/17
08:29
Recommendations
Beazer Homes analyst commentary  »

Beazer Homes price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:28
11/20/17
11/20
08:28
11/20/17
08:28
Conference/Events
The Board of Governors of the Federal Reserve System holds a closed meeting »

The Board of Governors of…

DG

Dollar General

$85.50

0.59 (0.69%)

, DLTR

Dollar Tree

$94.61

-0.02 (-0.02%)

08:28
11/20/17
11/20
08:28
11/20/17
08:28
Recommendations
Dollar General, Dollar Tree analyst commentary  »

Dollar General price…

DG

Dollar General

$85.50

0.59 (0.69%)

DLTR

Dollar Tree

$94.61

-0.02 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 07

    Dec

OMI

Owens & Minor

$19.14

0.23 (1.22%)

08:27
11/20/17
11/20
08:27
11/20/17
08:27
Recommendations
Owens & Minor analyst commentary  »

Owens & Minor price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIZZ

National Beverage

$102.23

0.32 (0.31%)

08:26
11/20/17
11/20
08:26
11/20/17
08:26
Upgrade
National Beverage rating change  »

National Beverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$93.61

-0.86 (-0.91%)

08:25
11/20/17
11/20
08:25
11/20/17
08:25
Recommendations
AbbVie analyst commentary  »

AbbVie estimates raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$19.13

0.09 (0.47%)

08:25
11/20/17
11/20
08:25
11/20/17
08:25
Downgrade
Deutsche Bank rating change  »

Deutsche Bank downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AMZN

Amazon.com

$1,129.88

-7.41 (-0.65%)

, CVS

CVS Health

$70.68

0.42 (0.60%)

08:25
11/20/17
11/20
08:25
11/20/17
08:25
Recommendations
Amazon.com, CVS Health, Walgreens Boots Alliance, Cardinal Health, McKesson, AmerisourceBergen, Thermo Fisher, Henry Schein, Patterson Companies analyst commentary  »

Amazon disruption of…

AMZN

Amazon.com

$1,129.88

-7.41 (-0.65%)

CVS

CVS Health

$70.68

0.42 (0.60%)

WBA

Walgreens Boots Alliance

$71.25

-0.05 (-0.07%)

CAH

Cardinal Health

$57.51

0.09 (0.16%)

MCK

McKesson

$142.13

-0.57 (-0.40%)

ABC

AmerisourceBergen

$78.84

-1.09 (-1.36%)

TMO

Thermo Fisher

$190.17

-0.44 (-0.23%)

HSIC

Henry Schein

$69.12

-0.39 (-0.56%)

PDCO

Patterson Companies

$36.04

-0.03 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

  • 12

    Dec

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.